EWTX Key Statistics, Chart & Performance
The current stock price of EWTX is 22.98 USD. In the past month the price increased by 27.88%. In the past year, price decreased by -29.49%.
EWTX Latest News, Press Relases and Analysis
EWTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 47.57 | 988.98B | ||
| JNJ | JOHNSON & JOHNSON | 19.79 | 494.92B | ||
| MRK | MERCK & CO. INC. | 11.47 | 250.76B | ||
| PFE | PFIZER INC | 7.86 | 143.00B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.36 | 98.22B | ||
| ZTS | ZOETIS INC | 19.63 | 54.84B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.62 | 22.82B | ||
| VTRS | VIATRIS INC | 4.6 | 12.34B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 23.43 | 11.17B | ||
| CORT | CORCEPT THERAPEUTICS INC | 91.77 | 8.50B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.16B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.26B |
Related stock screener links
About EWTX
Company Profile
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 126 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Company Info
EDGEWISE THERAPEUTICS INC
1715 38Th St
Boulder COLORADO 80303 US
CEO: Kevin Koch
Employees: 126
Phone: 17202627002
EDGEWISE THERAPEUTICS INC / EWTX FAQ
What does EWTX do?
Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company is headquartered in Boulder, Colorado and currently employs 126 full-time employees. The company went IPO on 2021-03-26. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The firm is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
Can you provide the latest stock price for EDGEWISE THERAPEUTICS INC?
The current stock price of EWTX is 22.98 USD. The price decreased by -9.06% in the last trading session.
Does EWTX stock pay dividends?
EWTX does not pay a dividend.
How is the ChartMill rating for EDGEWISE THERAPEUTICS INC?
EWTX has a ChartMill Technical rating of 8 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
What is the analyst forecast for EWTX stock?
19 analysts have analysed EWTX and the average price target is 37.03 USD. This implies a price increase of 61.16% is expected in the next year compared to the current price of 22.98.
How is the valuation of EDGEWISE THERAPEUTICS INC (EWTX) based on its PE ratio?
EDGEWISE THERAPEUTICS INC (EWTX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.58).
EWTX Technical Analysis
ChartMill assigns a technical rating of 8 / 10 to EWTX. When comparing the yearly performance of all stocks, EWTX is one of the better performing stocks in the market, outperforming 74.19% of all stocks.
EWTX Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to EWTX. No worries on liquidiy or solvency for EWTX as it has an excellent financial health rating, but there are worries on the profitability.
EWTX Financial Highlights
Over the last trailing twelve months EWTX reported a non-GAAP Earnings per Share(EPS) of -1.58. The EPS decreased by -5.33% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -24.57% | ||
| ROE | -25.58% | ||
| Debt/Equity | 0 |
EWTX Forecast & Estimates
19 analysts have analysed EWTX and the average price target is 37.03 USD. This implies a price increase of 61.16% is expected in the next year compared to the current price of 22.98.